PT-141 10mg

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist that was derived from melanotan II research. It is the first and only FDA-approved melanocortin-based therapeutic, approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 differs from MT-II by a single modification — the C-terminal amide is replaced with a free carboxylic acid — which alters its receptor selectivity and pharmacokinetic profile. PT-141's mechanism of action for sexual function is mediated primarily through MC4R activation in the central nervous system, particularly in hypothalamic regions involved in sexual arousal and desire. Unlike phosphodiesterase-5 inhibitors (sildenafil, etc.) which act peripherally on vascular smooth muscle, PT-141 acts centrally to modulate sexual desire and arousal pathways. This represents a fundamentally different pharmacological approach — it targets the 'wanting' component of sexual response rather than the mechanical erectile response. The peptide crosses the blood-brain barrier and activates MC4R-expressing neurons in the medial preoptic area and paraventricular nucleus of the hypothalamus. Downstream signaling involves oxytocin release and modulation of dopaminergic pathways. The 10mg vial provides a larger quantity for extended research protocols.

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist that was derived from melanotan II research. It is the first and only FDA-approved melanocortin-based therapeutic, approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 differs from MT-II by a single modification — the C-terminal amide is replaced with a free carboxylic acid — which alters its receptor selectivity and pharmacokinetic profile. PT-141's mechanism of action for sexual function is mediated primarily through MC4R activation in the central nervous system, particularly in hypothalamic regions involved in sexual arousal and desire. Unlike phosphodiesterase-5 inhibitors (sildenafil, etc.) which act peripherally on vascular smooth muscle, PT-141 acts centrally to modulate sexual desire and arousal pathways. This represents a fundamentally different pharmacological approach — it targets the 'wanting' component of sexual response rather than the mechanical erectile response. The peptide crosses the blood-brain barrier and activates MC4R-expressing neurons in the medial preoptic area and paraventricular nucleus of the hypothalamus. Downstream signaling involves oxytocin release and modulation of dopaminergic pathways. The 10mg vial provides a larger quantity for extended research protocols.

The FDA-approved dose of bremelanotide is 1.75 mg subcutaneously. Clinical trials studied doses from 0.75 mg to 4 mg. The 10mg vial provides sufficient material for extended research protocols.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.